Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Patients with rectal cancer whose disease is downstaged with neoadjuvant radiation therapy have better survival than their peers who fail to respond to…
NEW YORK (Reuters Health) – Yearly gynecological examinations fail to identify early stage ovarian cancer in women with a mutation in the BRCA1 or BRCA2 gene, a Dutch…
NEW YORK (Reuters Health) – New research suggests that B-cell clones may be a useful early marker for chronic lymphocytic leukemia (CLL) since they are found in nearly…
NEW YORK (Reuters Health) – In patients with diffuse cutaneous systemic sclerosis (dcSSc), treatment with rituximab depletes B cells in the peripheral circulation and in skin, with few…
NEW YORK (Reuters Health) – In premenopausal women with endocrine-responsive early breast cancer, addition of the bisphosphonate zoledronic acid to endocrine therapy significantly improves disease-free survival, physicians in…
With special guest Vince Papale, The Cancer Foundation For Personal Appearance hosts an event to promote cancer research, treatment and style. For more information, please visit: The Cancer…
NEW YORK (Reuters Health) – In patients with vestibular schwannomas related to neurofibromatosis type 2 (NF2), gamma knife radiosurgery can achieve good tumor control in about two-thirds of…
NEW YORK (Reuters Health) – The results of a randomized trial indicate that sequential and alternating chemotherapy with radiotherapy provide similar survival and larynx preservation in patients with…
NEW YORK (Reuters Health) – The addition of cetuximab to a fluoropyrimideine-based chemotherapy regimen reduces progression-free survival and worsens quality of life in patients with metastatic colorectal cancer,…
NEW YORK (Reuters Health) – While qualitative immunochemical fecal occult blood tests (FOBTs) may offer advantages over traditional guaiac-based FOBTs for colorectal cancer screening, there are large differences…
